

Preventive Services Payment Policy

Policy

Plan members have no member cost-sharing for preventive services rendered by in-network providers. Members may be required to pay a copayment, deductible, or coinsurance for non-preventive services received in conjunction with a preventive service visit, or for PPO members who receive preventive care from out-of-network providers.

Definitions

Preventive care: Services, tests, and immunizations that are intended to screen for diseases or conditions and to improve early detection of disease when there is no diagnosis or symptoms present. This includes immunizations, health maintenance visits (routine physical exams) for adults and children, as well as mammograms, Pap tests and other tests associated with the health maintenance visit, prenatal maternity care, well child care (including vision and auditory screening), voluntary family planning, nutrition counseling, and health education.

Reimbursement

Claims for preventive services must be submitted with service and diagnosis codes indicating that the service is preventive. Preventive ICD-10 codes must be in the primary diagnosis position. If another diagnosis is in the primary position on the claims, the service may be subject to member cost-sharing.

Reimbursement will be made for a preventive code with a problem focused code when modifier 25 is applied to the problem-focused code. Reimbursement for the preventive service will be made at 100% of the contracted rate, and reimbursement for the problem focused service will be made at 50% of the contracted rate. This should only occur when a significant abnormality or pre-existing condition is addressed and additional work is required to perform the key components of a problem focused E&M service, and services should be submitted on the same claim. Members have no copayment and/or deductible for routine physical exams. Medicare Advantage plan members will be responsible for a copayment and/or deductible when a problem-focused code with modifier 25 is included on the claim. Therefore, the appropriate use of modifier 25 is critical since it will be transparent to members. Beginning October 1, 2014, the Plan will not calculate a copayment and/or deductible for E&M codes submitted with modifier 25 when billed with annual preventive services for members enrolled in a commercial plan. Those services coded with modifier 25 will be regularly reviewed for coding accuracy.

The Plan reimburses advance care planning including the explanation and discussion of advance directives (CPT codes 99497 and 99498) with no member cost-share when provided with an annual preventive visit. Member cost-share will be required when these services are provided outside of the annual preventive visit.

Billing/coding guidelines

In order for a service to be considered preventive care, a preventive diagnosis must be the primary diagnosis on the claim. In addition, each claim line should indicate the applicable diagnosis. In cases where the diagnosis is not preventive in nature, cost-sharing will apply. The below coding represents services and diagnose codes that the Plan considers preventive, while the below listed are considered preventive there may be other preventive benefits available based upon the member's plan type. As some CPT/HCPCS codes can be both preventive and diagnostic the appropriate preventive diagnostic code should be billed.

Abdominal Aortic Aneurysm (AAA): Screening

Code	Description	Guidance/Instructions
76706	Ultrasound, abdominal aorta, real time with image documentation, screening study for abdominal	For commercial and MassHealth members, AAA

	aortic aneurysm (AAA)	<p>screening is covered in accordance with the USPSTF A and B recommendations in effect at the time the service is rendered (Date of current recommendation: December 10, 2019). For commercial and MassHealth members, the Plan covers one-time ultrasound screening for AAA for men aged 65 to 75 years who have ever smoked.</p> <p>Effective for dates of service on or after January 1, 2007, a one-time ultrasound screening for AAA is covered for eligible Medicare members.*</p> <p>No specific diagnosis code requirements.</p>
--	-----------------------	---

* An eligible Medicare member is one who meets all of the following criteria:

- Receives a referral for such an ultrasound screening as a result of an initial preventive physical examination (IPPE), also known as the Welcome to Medicare visit, from a physician or qualified non-physician practitioner (physician assistant, nurse practitioner or clinical nurse specialist);
- Receives such ultrasound screening from a provider or supplier who is authorized to provide covered ultrasound diagnostic services for plan members;
- Has not been previously furnished such an ultrasound screening under the Medicare Program; and
- Is included in at least one of the following risk categories:
 - Has a family history of abdominal aortic aneurysm;
 - Is a man age 65 to 75 who has smoked at least 100 cigarettes in his lifetime;
 - Is a beneficiary, who manifests other risk factors in a beneficiary category recommended for screening by the United States Preventive Services Task Force regarding AAA, as specified by the Secretary of Health and Human Services, through the national coverage determinations process.

Unhealthy Alcohol Use in Adults: Screening and Behavioral Counseling Interventions

The USPSTF recommends screening for unhealthy alcohol use in primary care settings in adults 18 years or older, including pregnant women, and providing persons engaged in risky or hazardous drinking with brief behavioral counseling interventions to reduce unhealthy alcohol use (Date of current recommendation: November 2018).

Structured screening for unhealthy alcohol use and brief intervention services (CPT 99408-99409) may be reported for commercial plan members age 18 years of age and older when performed as part of the treatment of condition(s) related to or potentially exacerbated by the behavior or when performed to change the harmful behavior that has not yet resulted in illness.

CPT codes 99408 and 99409 cannot be billed when screening results are negative because there is no required intervention.

Any Evaluation and Management Service reported on the same day must be distinct and reported with modifier 25. Time spent providing structured screening and brief intervention services may not be used as a basis for the Evaluation and Management code selection. Structured screening and brief intervention services involve specific validated interventions of assessing readiness for change and barriers to change (for example, Alcohol Use Disorders Identification Test), advising a change in behavior, assisting by providing suggested actions and motivational counseling, and arranging for services and follow-up.

Effective March 1, 2023, CPT codes 99408 and 99409 are not covered for MassHealth ACO plan members in accordance with MassHealth program regulations.

Effective March 1, 2023, CPT codes 99408 and 99409 are not covered for Medicare plan members (Fallon Medicare Plus, NaviCare and PACE). See Screening and Behavioral Counseling Interventions in Primary Care to Reduce Alcohol Misuse below.

Code	Description	Guidance/Instructions
99408	Alcohol and/or substance (other than tobacco) abuse structured screening (eg, AUDIT, DAST), and brief intervention (SBI) services; 15 to 30 minutes	No specific diagnosis code requirements.
99409	Alcohol and/or substance (other than tobacco) abuse structured screening (eg, AUDIT, DAST), and brief intervention (SBI) services; greater than 30 minutes	

Screening and Behavioral Counseling Interventions in Primary Care to Reduce Alcohol Misuse

For Medicare plan members (Fallon Medicare Plus, NaviCare and PACE), alcohol misuse screening and counseling is covered once per year for members who use alcohol but don't meet criteria for alcohol dependence. For those who screen positive, up to 4 brief face-to-face counseling sessions per year are covered (NCD 210.8 Screening and Behavioral Counseling Interventions in Primary Care to Reduce Alcohol Misuse).

Nationally Covered Indications

- Who misuse alcohol, but whose levels or patterns of alcohol consumption do not meet criteria for alcohol dependence (defined as at least three of the following: tolerance, withdrawal symptoms, impaired control, preoccupation with acquisition and/or use, persistent desire or unsuccessful efforts to quit, sustains social, occupational, or recreational disability, use continues despite adverse consequences); and
- Who are competent and alert at the time that counseling is provided; and,
- Whose counseling is furnished by qualified primary care physicians or other primary care practitioners in a primary care setting.

Services covered under this NCD must be provided by a primary care provider or by a provider in a primary care setting. Emergency departments, inpatient hospital settings, ambulatory surgical centers, independent diagnostic testing facilities, skilled nursing facilities, inpatient rehabilitation facilities and hospices are not considered primary care settings for the purposes of alcohol misuse screening and counseling.

G0442 and G0443 are payable on the same date of service (exception: FQHCs and RHCs). Only one unit of G0443 is payable per date of service.

A separately identifiable Evaluation and Management service can be billed (with modifier 25) on the same date of service. It must be documented that the reason for the visit was unrelated to the alcohol misuse screening.

Code	Description	Guidance/Instructions
G0442	Annual alcohol misuse screening, 15 minutes	No specific diagnosis code requirements.
G0443	Brief face-to-face behavioral counseling for alcohol misuse, 15 minutes	

Asymptomatic Bacteriuria in Adults: Screening

The USPSTF recommends screening for asymptomatic bacteriuria using urine culture in pregnant persons. The USPSTF recommends against screening for asymptomatic bacteriuria in nonpregnant adults. Screening of pregnant persons for asymptomatic bacteriuria using a midstream, clean-catch urine culture should occur at the first prenatal visit or at 12 to 16 weeks of gestation, whichever is earlier.

Code	Description	Guidance/Instructions
87081	Culture, presumptive, pathogenic organisms, screening only	For commercial and MassHealth members, screening for asymptomatic bacteriuria is covered in accordance with the USPSTF A and B recommendations in effect at the time the service is rendered (Date of current recommendation: September 24, 2019). ICD-10-CM diagnosis code requirements: Z34.00-Z34.93 - Encounter for supervision of normal pregnancy O09.00-O09.93 – Supervision of high-risk pregnancy O36.80x0-O36.80x9 – Pregnancy with inconclusive fetal viability
87084	Culture, presumptive, pathogenic organisms, screening only; with colony estimation from density chart	
87086	Culture, bacterial; quantitative colony count, urine	
87088	Culture, bacterial; with isolation and presumptive identification of each isolate, urine	

MassHealth Developmental and Behavioral Health Screening in Pediatric Primary Care

MassHealth requires primary care providers (PCPs) to offer screening for members younger than 21 years during each well-child visit, and as needed during other non-routine visits.

Effective January 1, 2023, MassHealth will discontinue listing specific screening tools in Appendix W and will instead point to [Instruments for Recommended Universal Screening at Specific Bright Futures Visits](#) (Bright Futures Toolkit) published by the American Academy of Pediatrics (AAP) (per [MassHealth All Provider Bulletin 348](#)).

Effective September 1, 2022, MassHealth will differentiate between developmental and behavioral health screening and effective will reimburse for autism screening (per [MassHealth Transmittal Letter PHY-164](#)), as indicated below:

- **Developmental Screening** - For members from birth through 3 years (to the 4th birthday), pediatric primary care providers must offer to administer and score an age-appropriate developmental screening tool selected from among those listed in the Bright Futures Toolkit at each well-child visit or as needed during non-routine visits. Claims for developmental

screening must be submitted with CPT code 96110 and modifier U1 (no need identified) or modifier U2 (need identified).

- **Autism Screening** - In addition to developmental screening, it is strongly recommended that pediatric primary care providers conduct screening for Autism at the 18- and 24-month well-child visits. Autism screening tools must be selected from those listed in the Bright Futures Toolkit. PCPs may submit a second claim at the 18- and 24-month well-child visit with CPT 96110 and modifier U3 (no further follow-up needed) or U4 (further follow-up needed).
- **Behavioral Health Screening** - For members ages 4 to 21 years (to the 21st birthday), pediatric primary care providers must offer to administer and score an age-appropriate behavioral health screening tool selected from among those listed in the Bright Futures Toolkit at each well-visit or as needed during non-routine visits. Claims for behavioral health screening must be submitted with CPT code 96127 and modifier U1 (no need identified) or U2 (need identified). When behavioral health needs are identified, providers must refer members to appropriate follow-up services.

Effective for dates of service on or after September 1, 2021, members younger than age 21 are eligible for preventive behavioral health services if they have a positive behavioral health screen (or, in the case of an infant, a positive post-partum depression screening), even if they do not meet criteria for behavioral health diagnosis and therefore do not meet medical necessity criteria for behavioral health treatment.

- **Maternal and Caregiver Depression Screening** – For members 6 months of age and younger, pediatric primary care providers must continue maternal and caregiver depression screening by administering either the Edinburgh Postnatal Depression Scale (EPDS) or the Survey of Well-being of Young Children (SWYC) during a well-child visit or as needed during non-routine visits. Providers must submit claims for maternal and caregiver depression screening with CPT code 96110 and modifier U1 (no need identified) or modifier U2 (need identified), and modifier UD to indicate maternal and caregiver depression screening, using the infant’s member ID.

Claims for CPT 96110 submitted for MassHealth ACO members 21 years of age and older will deny. Claims for CPT 96110 submitted without a U modifier will deny.

“Developmental health need identified” means the provider administering the screening tool, in their professional judgment, identified a child with a potential developmental health services need.

“Behavioral health need identified” means the provider administering the screening tool, in their professional judgment, identified a child with a potential behavioral health services need.

Code	Modifier	Description
96110	U1	Covered for members birth through 3 years old for the administration and scoring of a standardized developmental health screening tool selected from the list referenced in Appendix W* of your MassHealth provider manual; with no developmental health need identified.
96110	U2	Covered for members birth through 3 years old for the administration and scoring of a standardized developmental health screening selected from the list referenced in Appendix W* of your MassHealth provider manual; with developmental health need identified.
96127	U3	Covered for members 18- and 24 months for the administration and scoring of a standardized Autism screening tool selected from the list referenced in Appendix W* of your MassHealth provider manual; with no further follow up needed.
96127	U4	Covered for members 18- and 24 months for the administration and scoring of a standardized Autism screening tool selected from the list

		referenced in Appendix W* of your MassHealth provider manual; with further follow up needed.
96110	UD	Covered for members birth to 6 months for the administration and scoring of the Edinburgh Postnatal Depression Scale with member's caregiver. UD must be used together with either U1 or U2.

* Effective January 1, 2023, MassHealth will discontinue listing specific screening tools in Appendix W and will instead point to Instruments for Recommended Universal Screening at Specific Bright Futures Visits (Bright Futures Toolkit) published by the American Academy of Pediatrics (AAP).

Birth Control

Code	Description	Guidance/ Instructions
00851	Anesthesia for intraperitoneal procedures in lower abdomen including laparoscopy; tubal ligation/transection	The Plan covers Birth Control as preventative based upon the <u>FDA Approved Categories</u>
00952	Anesthesia for vaginal procedures (including biopsy of labia, vagina, cervix or endometrium); hysteroscopy and/or hysterosalpingography	
11976	Removal, implantable contraceptive capsules	Pharmacy related benefits can be located <u>Here</u>
11981	Insertion, non-biodegradable drug delivery implant	
11982	Removal, non-biodegradable drug delivery implant	Please bill with the appropriate encounter code range encounters for contraceptive management Z30.0- Z30.9
11983	Removal with reinsertion, non-biodegradable drug delivery implant	
57170	Diaphragm or cervical cap fitting with instructions	
58300	Insertion of intrauterine device (IUD)	
58301	Removal of intrauterine device (IUD)	
58565	Hysteroscopy, surgical; with bilateral fallopian tube cannulation to induce occlusion by placement of permanent implants	
58600	Ligation or transection of fallopian tube(s), abdominal or vaginal approach, unilateral or bilateral	
58615	Occlusion of fallopian tube(s) by device (eg, band, clip, Falope ring) vaginal or suprapubic approach	
58670	Laparoscopy, surgical; with fulguration of oviducts (with or without transection)	
58671	Laparoscopy, surgical; with occlusion of oviducts by device (eg, band, clip, or Falope ring)	
A4261	Cervical cap for contraceptive use	
A4266	Diaphragm for contraceptive use	
J7296	Levonorgestrel-releasing intrauterine contraceptive system, (Kyleena), 19.5 mg	
J7297	Levonorgestrel-releasing intrauterine contraceptive system (Liletta), 52 mg	
J7298	Levonorgestrel-releasing intrauterine contraceptive system (Mirena), 52 mg	
J7300	Intrauterine copper contraceptive	
J7301	Levonorgestrel-releasing intrauterine contraceptive system (Skyla), 13.5 mg	
J7303	Contraceptive supply, hormone containing vaginal ring, each	
J7307	Etonogestrel (contraceptive) implant system, including implant and supplies	

BRCA

Code	Description	Guidance/Instructions
81212	BRCA1, BRCA2 (breast cancer 1 and 2) (eg, hereditary breast and ovarian cancer) gene analysis; 185delAG, 5385insC, 6174delT variants	Prior Authorization is required Considered preventive only when meeting the USPSTF B level recommendation here: <u>Recommendation</u>
81215	BRCA1 (breast cancer 1) (eg, hereditary breast and ovarian cancer) gene analysis; known familial variant	
81216	BRCA2 (breast cancer 2) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis	Use a below diagnoses code to indicate preventative Z80.0: Family history of malignant neoplasm of digestive organs Z80.3: Family history of malignant neoplasm of breast Z80.41: Family history of malignant neoplasm of ovary Z80.49: Family history of malignant neoplasm of other genital organs
81217	BRCA2 (breast cancer 2) (eg, hereditary breast and ovarian cancer) gene analysis; known familial variant	

Breast Cancer Screening

Code	Description	Guidance/Instructions
77053	Mammary ductogram or galactogram, single duct, radiological supervision and interpretation	Use appropriate screening diagnostic codes Z12.31: Encounter for screening mammogram for malignant neoplasm of breast Z12.39 : Encounter for other screening for malignant neoplasm of breast
77054	Mammary ductogram or galactogram, multiple ducts, radiological supervision and interpretation	
77061	Digital breast tomosynthesis; unilateral	
77062	Digital breast tomosynthesis; bilateral	
77063	Screening digital breast tomosynthesis, bilateral (List separately in addition to code for primary procedure)	
77065	Diagnostic mammography, including computer-aided detection (CAD) when performed; unilateral	
77066	Diagnostic mammography, including computer-aided detection (CAD) when performed; bilateral	
77067	Screening mammography, bilateral (2-view study of each breast), including computer-aided detection (CAD) when performed	

Cervical Cancer Screening

Code	Description	Guidance/Instructions
88141-88175	Cytopath codes	Cervical Cancer Screening should be performed in accordance with the USPSTF <u>recommendation</u> ICD-10 Codes Z01.411: Encounter for gynecological examination (general) (routine) with abnormal findings

		Z01.419: Encounter for gynecological examination (general) (routine) without abnormal findings Z12.4: Encounter for screening for malignant neoplasm of cervix
--	--	---

Chlamydia and Gonorrhea Screening for Women

Code	Description	Guidance/Instructions
87491	Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique	Chlamydia and Gonorrhea screenings are appropriate for woman as outlined by USPSTF Recommendation
87591	Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique	

Colorectal Cancer Screening

Commercial and MassHealth members

What's new: Effective May 18, 2021, the USPSTF has expanded the recommended ages for colorectal cancer screening to 45 to 75 years of age (previously it was 50 to 75 years).

Recommended screening strategies include:

- High-sensitivity guaiac fecal occult blood test (HSgFOBT) or fecal immunochemical test (FIT) every year
- Stool DNA-FIT every 1 to 3 years
- Computed tomography colonography every 5 years
- Flexible sigmoidoscopy every 5 years
- Flexible sigmoidoscopy every 10 years + annual FIT
- Colonoscopy screening every 10 years

Code	Description	Guidance/Instructions
00811	Anesthesia for lower intestinal endoscopic procedures, endoscope introduced distal to duodenum; not otherwise specified	For commercial and MassHealth members, colorectal cancer screening is covered in accordance with the USPSTF A and B Recommendations in effect at the time the service is rendered (Colorectal Cancer: Screening, updated May 18, 2021). ICD-10 Codes Z12.11: Encounter for screening for malignant neoplasm of colon Z80.0: Family history of malignant neoplasm of digestive organs The ICD-10 definition of a screening is Screening is the testing for disease or disease precursors in seemingly well individuals so that early
00812	Anesthesia for lower intestinal endoscopic procedures, endoscope introduced distal to duodenum; screening colonoscopy	
45330	Sigmoidoscopy, flexible; diagnostic, with or without collection of specimen(s) by brushing or washing	
45331	Sigmoidoscopy, flexible; with biopsy, single or multiple	
45332	Sigmoidoscopy, flexible; with removal of foreign body(s)	
45333	Sigmoidoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) by hot biopsy forceps	
45334	Sigmoidoscopy, flexible; with control of bleeding, any method	
45335	Sigmoidoscopy, flexible; with directed submucosal injection(s), any substance	
45337	Sigmoidoscopy, flexible; with decompression (for pathologic distention) (eg, volvulus, megacolon), including placement of decompression tube, when performed	
45338	Sigmoidoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) by snare technique	

45340	Sigmoidoscopy, flexible; with transendoscopic balloon dilation	<p>detection and treatment can be provided for those who test positive for the disease.</p> <p>Note: Computed tomographic (CT) colonography, diagnostic, including image postprocessing, with or without contrast (74261/74262) requires prior authorization</p>
45341	Sigmoidoscopy, flexible; with endoscopic ultrasound examination	
45342	Sigmoidoscopy, flexible; with transendoscopic ultrasound guided intramural or transmural fine needle aspiration/biopsy(s)	
45346	Sigmoidoscopy, flexible; with ablation of tumor(s), polyp(s), or other lesion(s) (includes pre- and post-dilation and guide wire passage, when performed)	
45378	Colonoscopy, flexible; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure)	
45379	Colonoscopy, flexible; with removal of foreign body(s)	
45380	Colonoscopy, flexible; with biopsy, single or multiple	
45381	Colonoscopy, flexible; with directed submucosal injection(s), any substance	
45382	Colonoscopy, flexible; with control of bleeding, any method	
45384	Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) by hot biopsy forceps	
45385	Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) by snare technique	
45386	Colonoscopy, flexible; with transendoscopic balloon dilation	
45388	Colonoscopy, flexible; with ablation of tumor(s), polyp(s), or other lesion(s) (includes pre- and post-dilation and guide wire passage, when performed)	
45391	Colonoscopy, flexible; with endoscopic ultrasound examination limited to the rectum, sigmoid, descending, transverse, or ascending colon and cecum, and adjacent structures	
45392	Colonoscopy, flexible; with transendoscopic ultrasound guided intramural or transmural fine needle aspiration/biopsy(s), includes endoscopic ultrasound examination limited to the rectum, sigmoid, descending, transverse, or ascending colon and cecum, and adjacent structures	
74261	Computed tomographic (CT) colonography, diagnostic, including image postprocessing; without contrast material	
74262	Computed tomographic (CT) colonography, diagnostic, including image postprocessing; with contrast material(s) including non-contrast Images, if performed	
81528	<p>Oncology (colorectal) screening, quantitative real-time target and signal amplification of 10 DNA markers (KRAS mutations, promoter methylation of NDRG4 and BMP3) and fecal hemoglobin, utilizing stool, algorithm reported as a positive or negative result</p> <p>Use for Cologuard™ multitarget stool DNA (sDNA)</p>	

	test	
82270	Blood, occult, by peroxidase activity (eg, guaiac), qualitative; feces, consecutive collected specimens with single determination, for colorectal neoplasm screening (ie, patient was provided 3 cards or single triple card for consecutive collection) Use for HSgFOBT	
82274	Blood, occult, by fecal hemoglobin determination by immunoassay, qualitative, feces, 1-3 simultaneous determinations Use for Fecal Immunochemical Test (FIT), such as InSure®	
99151	Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intraservice time, patient younger than 5 years of age	
99152	Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intraservice time, patient age 5 years or older	
99153	Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; each additional 15 minutes intraservice time (List separately in addition to code for primary service)	
99155	Moderate sedation services provided by a physician or other qualified health care professional other than the physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports; initial 15 minutes of intraservice time, patient younger than 5 years of age	
99156	Moderate sedation services provided by a physician or other qualified health care professional other than the physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports; initial 15 minutes of intraservice time, patient age 5 years or older	

99157	Moderate sedation services provided by a physician or other qualified health care professional other than the physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports; each additional 15 minutes intraservice time (List separately in addition to code for primary service)	
-------	---	--

Colorectal Cancer Screening

Medicare members

What's new: Effective for dates of service on or after January 1, 2023, coverage for the following colorectal cancer screening tests will begin at age 45 (reduced from 50 to 45): blood-based biomarker tests, Cologuard (multi-target stool DNA (MT sDNA) test, immunoassay-based fecal occult blood tests (iFOBT), guaiac-based fecal occult blood tests (gFOBT), barium enema and flexible sigmoidoscopy. Screening colonoscopy does not have a minimum age requirement under Medicare coverage. Also, effective for dates of service on or after January 1, 2023, the definition of colorectal cancer screening test will include a follow-up screening colonoscopy when a non-invasive stool-based colorectal cancer screening test (FOBT or Cologuard) returns a positive result.

Code	Description	Guidance/Instructions
00811	Anesthesia for lower intestinal endoscopic procedures, endoscope introduced distal to duodenum; not otherwise specified	<p>For Medicare members, colorectal cancer screening for is covered in accordance with the Medicare Benefit Policy Manual, Chapter 15, Section 60, and the National Coverage Determination (NCD) for Colorectal Cancer Screening Tests (210.3)</p> <p>ICD-10 Codes Z86.004</p> <p>For multitarget sDNA testing and blood-based testing, use ICD-10 codes Z12.11 and Z12.12</p> <p>For additional information on coverage for colorectal cancer screening services, refer to Medicare Preventive Services Chart¹</p>
00812	Anesthesia for lower intestinal endoscopic procedures, endoscope introduced distal to duodenum; screening colonoscopy	
81528 ²	<p>Oncology (colorectal) screening, quantitative real-time target and signal amplification of 10 DNA markers (KRAS mutations, promoter methylation of NDRG4 and BMP3) and fecal hemoglobin, utilizing stool, algorithm reported as a positive or negative result</p> <p>Use for Cologuard™ multitarget stool DNA (MT sDNA) test.</p> <p>Cologuard (MT sDNA) is covered once every three years for Medicare members who meet all of the following criteria:</p> <ul style="list-style-type: none"> • Age 45-85 years, and • Asymptomatic, and • At average risk of developing colorectal cancer. 	
82270	Blood, occult, by peroxidase activity (eg, guaiac), qualitative; feces, consecutive collected specimens with single determination, for colorectal neoplasm screening (ie, patient was provided 3 cards or single triple card for consecutive collection)	

¹ Medicare Preventive Services Chart available at: <https://www.cms.gov/Medicare/Prevention/PrevntionGenInfo/medicare-preventive-services/MPS-QuickReferenceChart-1.html>.

² HCPCS code G0464 expired on December 31, 2015, and has been replaced with CPT code 81528, Oncology (colorectal) screening, quantitative real-time target and signal amplification of 10 DNA markers (KRAS mutations, promoter methylation of NDRG4 and BMP3) and fecal hemoglobin, utilizing stool, algorithm reported as a positive or negative result, effective January 1, 2016.

	Use for HSgFOBT	
G0104	Colorectal cancer screening; flexible sigmoidoscopy NOTE: If during the course of a screening flexible sigmoidoscopy a lesion or growth is detected which results in a biopsy or removal of the growth; the appropriate diagnostic procedure classified as a flexible sigmoidoscopy with biopsy or removal along with modifier –PT should be billed rather than HCPCS G0104.	
G0105	Colorectal cancer screening; colonoscopy on individual at high risk NOTE: If during the course of the screening colonoscopy, a lesion or growth is detected which results in a biopsy or removal of the growth, the appropriate diagnostic procedure classified as a colonoscopy with biopsy or removal along with modifier –PT should be billed and paid rather than HCPCS G0105. When a covered colonoscopy is attempted but cannot be completed because of extenuating circumstances, the Plan will pay for the interrupted colonoscopy as long as the coverage conditions are met for the incomplete procedure. When submitting a claim for the interrupted colonoscopy, professional providers are to suffix the colonoscopy code with a modifier of -53 to indicate that the procedure was interrupted. When submitting a facility claim for an interrupted colonoscopy, use modifier -73 or -74 as appropriate.	
G0106	Colorectal cancer screening; alternative to G0104, screening sigmoidoscopy, barium enema	
G0120	Colorectal cancer screening; alternative to G0105, screening colonoscopy, barium enema	
G0121	Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk	
G0327	Colorectal cancer screening; blood-based biomarker The currently available Epi proColon® (Epigenomics) and ColoVantage (Quest Diagnostics) blood-based biomarker colorectal cancer screening tests do not meet Medicare criteria. At this time, Epi proColon® test and Colovantage are not covered tests.	
G0328	Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous Use for Fecal Immunochemical Test (FIT), such as InSure®	
G0500	Moderate sedation services provided by the same physician or other qualified health-care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an	

	<p>independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time, patient age 5 years or older.</p> <p>Report G0500 for all endoscopic procedures where moderate sedation is inherent to the procedure.</p> <p>Additional time may be reported with 99153, as appropriate.</p>	
99153	Moderate sedation services provided by the same physician or other qualified health-care professional performing the diagnostic or therapeutic service that the sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; each additional 15 minutes of intra- service time (List separately in addition to code for primary service).	

Depression Screening

Code	Description	Guidance/Instructions
G0444	Annual depression screening, 15 minutes	<p>Bill with a screening code if billed with part of other preventative services.</p> <p>Specific Diagnosis Code Z13.3: Encounter for screening examination for mental health and behavioral disorders</p>

Fluoride Varnish

Code	Description	Guidance/Instructions
99188	Application of topical fluoride varnish by a physician or other qualified health care professional	Appropriate for children in accordance with the USPSTF Recommendation
D1206	<p>Topical application of fluoride varnish</p> <p>D1206 should only be used by dentists to bill for topical application of fluoride varnish for plan members with preventive dental coverage.</p>	Bill with an appropriate encounter code related to a newborn Z00.1 range or child Z00.12 range

Hearing Screening in Children

American Academy of Audiology Childhood Hearing Screening Guidelines³ recommendations for hearing screening:

1. Screen children age 3 (chronologically and developmentally) and older using pure tone screening.
2. Otoacoustic emissions (OAE) should be used only when screening preschool and school age children for whom pure tone screening is not developmentally appropriate (ability levels < 3 years).

³ Available at: <https://www.cdc.gov/ncbddd/hearingloss/recommendations.html>.

3. Tympanometry should be used as a second-stage screening method following failure of pure tone or otoacoustic emissions screening.

Code	Description	Guidance/Instructions
92551	Screening test, pure tone, air only	ICD-10 Codes Z00.121 Routine child health exam with abnormal findings Z00.129 Routine child health exam without abnormal findings
92558	Evoked otoacoustic emissions, screening (qualitative measurement of distortion product or transient evoked otoacoustic emissions), automated analysis	
92567	Tympanometry (impedance testing)	

Note: ICD-10 codes Z01.10 (encounter for examination of ears and hearing without abnormal findings) and Z01.118 (encounter for examination of ears and hearing with other abnormal findings) are reported only when a child presents for an encounter specific to ears and hearing, not for a routine well-child examination at which a hearing screening is performed.

Hepatitis B Virus Screening

Code	Description	Guidance/Instructions
87340	Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; hepatitis B surface antigen (HBsAg)	The USPSTF recommends screening for those at high risk and for pregnant women Please utilize these diagnoses for high risk Z11.3 (Encounter for screening for infections with a predominantly sexual mode of transmission) Z11.59 (Encounter for screening for other viral diseases)
87341	Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; hepatitis B surface antigen (HBsAg) neutralization	
G0499	Hepatitis B screening in non-pregnant, high risk individual includes hepatitis B surface antigen (HBSAG) followed by a neutralizing confirmatory test for initially reactive results, and antibodies to HBSAG (anti-HBS) and hepatitis B core antigen (anti-HBC)	Please utilize an appropriate encounter code related to pregnancy for pregnant woman

Hepatitis C Virus Screening for Commercial and MassHealth Members

What's new: Effective March 2, 2020, the USPSTF expanded the population that should be screened for Hepatitis C virus to include asymptomatic adults aged 18 to 79 years (including pregnant women) without known liver disease. Previously the USPSTF recommended Hepatitis C virus screening in adults born between 1945 and 1965 and others at high risk.

Most adults should only be screened once per lifetime. Persons with continued risk for HCV infection (e.g., past or current injected drug use) should be screened periodically.

Note: A positive screening Hepatitis C antibody test result may be followed by diagnostic PCR (polymerase chain reaction) testing (e.g., CPT 87522). Diagnostic lab testing for commercial members is subject to member cost-sharing.

Code	Description	Guidance/Instructions
86803	Hepatitis C antibody;	For commercial and MassHealth members, Hepatitis C virus screening is covered in accordance with

		<p>the USPSTF A and B Recommendations in effect at the time the service is rendered: Hepatitis C Virus Infection in Adolescents and Adults: Screening (Updated March 2, 2020).</p> <p>Please utilize these diagnoses for high risk Z11.3 (Encounter for screening for infections with a predominantly sexual mode of transmission) Z11.59 (Encounter for screening for other viral diseases)</p>
--	--	--

Hepatitis C Virus Screening for Medicare Members

Code	Description	Guidance/Instructions
G0472	<p>Hepatitis C antibody screening, for individual at high risk and other covered indication(s)</p> <p>Please note: G0472 is the only code that should be reported for Hepatitis C screening under Medicare NCD 210.13 (MM9200).</p>	<p>For Medicare members, Hepatitis C screening is covered in accordance with the Medicare NCD for Screening for Hepatitis C Virus (HCV) in Adults (210.13)</p> <p>ICD-10 Codes Z72.89, F19.20</p>

HPV Screening

Code	Description	Guidance/Instructions
87623	Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), low-risk types (eg, 6, 11, 42, 43, 44)	Screenings will be covered based upon the <u>USPSTF Recommendation</u>
87624	Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), high-risk types (eg, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68)	Please utilize these diagnoses for high risk Z11.3 (Encounter for screening for infections with a predominantly sexual mode of transmission) Z11.59 (Encounter for screening for other viral diseases)
87625	Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), types 16 and 18 only, includes type 45, if performed	

HIV Preexposure Prophylaxis (PrEP) for commercial and MassHealth ACO members

On June 11, 2019, the USPSTF released a recommendation that clinicians offer preexposure prophylaxis (PrEP) with effective antiretroviral therapy to persons who are at high risk of HIV acquisition. See Clinical Considerations on pages 2205-2206 of the USPSTF Recommendation Statement⁴ for information about the identification of persons at high risk of HIV acquisition.

⁴ The full USPSTF Recommendation Statement is available at: <https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/prevention-of-human-immunodeficiency-virus-hiv-infection-pre-exposure-prophylaxis>.

The USPSTF recommendation cites CDC guidelines⁵ advise that PrEP is a comprehensive intervention comprised of antiretroviral medication and essential support services (including medication self-management/adherence counseling, risk reduction strategies, and mental health counseling, etc.) that ensure PrEP is administered safely and effectively to plan members who need it.

All persons whose sexual or drug injection history indicates consideration of PrEP and who are interested in taking PrEP must undergo laboratory testing to identify those for whom this intervention would be harmful or for whom it would present specific health risks that would require close monitoring. Tests include HIV testing, Hepatitis B and C testing, pregnancy testing (if applicable), testing for renal insufficiency (creatinine testing and calculated estimated creatinine clearance (eCrCl) or glomerular filtration rate (eGFR)) and screening for sexually transmitted infections (STIs).

Recommended ICD-10-CM codes

Office visits must include a principal diagnosis/first-listed condition to be billable. Z20.6 (Contact with and (suspected) exposure to HIV), is classified as an acceptable principal diagnosis in the ICD-10-CM system. Use Z20.6 when coding PrEP office visits.

Lab tests prior to initiation use screening codes:

- Z11.4 - Encounter for screening for HIV
- Z11.3 - Encounter for screening for infections with a predominantly sexual mode of transmission
- Z11.59 - Encounter for screening for other viral diseases

Subsequent lab tests (related to the ongoing risk of HIV, STD or HCV infection while taking PrEP) use contact with codes:

- Z20.6 - Contact with and (suspected) exposure to HIV
- Z20.2 - Contact with and (suspected) exposure to infections with a predominantly sexual mode of transmission
- Z20.5 – Contact with and (suspected) exposed to viral hepatitis

Use Z71.7 (HIV counseling) for adherence counseling (99401-99404).

Use Z11.3, Z11.4, Z20.2 or Z20.6 for preventive counseling and risk factor reduction (99401-99404) provided with baseline and periodic HIV and STI screening.

Lab tests ordered to evaluate conditions potentially associated with long-term use of PrEP medication (i.e., creatinine to assess for potential kidney injury) should include Z79.899 (Other long term (current) drug therapy).

Recommended CPT codes

Code(s)	Description	Guidance/Instructions
99202-99205	Office visit or other outpatient visit for the evaluation and management of a new patient	Office visits - Office visits are covered when the primary purpose of the office visit is the delivery of a component of the USPSTF recommendation that is not billed separately,
99211-99215	Office visit or other outpatient visit for the evaluation and management of an established patient	
86701	HIV-1	HIV testing - Plan members

⁵. Preexposure Prophylaxis for the Prevention of HIV Infection in the United States – 2021 Update A Clinical Practice Guideline, available at: <https://www.cdc.gov/hiv/guidelines/preventing.html>. A guide to billing codes for PrEP coverage is available at <https://www.nastad.org/resource/billing-coding-guide-hiv-prevention>.

86702	HIV-2	must be tested and confirmed to be uninfected before starting PrEP and tested again for HIV every three months while taking PrEP
86703	HIV-1 and HIV-2, single result	
87389	HIV-1 antigen(s), with HIV-1 and HIV-2 antibodies, single result	
87535	HIV-1, amplified probe technique, includes reverse transcription when performed	
86704	Hepatitis B core antibody (HBc-Ab); total	Baseline Hepatitis B testing – Hepatitis B virus infection is not a contraindication to PrEP, but plan members being considered for PrEP must be screened so that when the PrEP medication, which suppresses HBV replication in the liver, is stopped, the plan member can be monitored to ensure safety and to rapidly identify any potential injury.
86706	Hepatitis B surface antibody (HBsAb)	
87340	Hepatitis B surface antigen (HBsAG)	
87341	Hepatitis B surface antigen (HBsAG) neutralization	
86803	Hepatitis C antibody	Hepatitis C testing – Plan members should be screened at baseline for hepatitis C virus infection. Plan members with ongoing risk of contracting hepatitis C should be screened periodically consistent with CDC guidelines for hepatitis C screening.
86804	Hepatitis C antibody; confirmatory test (e.g., immunoblot)	
82565	Creatinine; blood	Creatinine testing with calculation of estimated creatine clearance (eCrCl) or glomerular filtration rate (eGFR) – The estimated eCrCl or eGFR must be measured and calculated before beginning PrEP to assess if kidney function is in the range for safe prescribing of PrEP medication. Creatinine and eCrCL or eGFR should be checked periodically consistent with CDC guidelines while on PrEP medication to assess for potential kidney injury and to ensure that it is safe to continue PrEP medication.
87491	Chlamydia trachomatis, amplified probe technique	Testing for sexually transmitted infections (STIs) – Persons must be screened for STIs at baseline and should be screened periodically thereafter consistent with CDC guidelines, which may require multiple anatomic site testing
87591	Neisseria gonorrhoeae, amplified probe technique	
87801	Infectious agent detection by nucleic acid (DNA or RNA), multiple organisms; amplified probe technique Use when performing combined chlamydia and gonorrhea testing	

86592	Syphilis test, non-treponemal antibody; qualitative	(i.e., genital, oropharyngeal, and rectal) for gonorrhea and chlamydia, and testing for syphilis, together with behavioral counseling, which are recommended to reduce the risk of STIs, the presence of which may increase the likelihood of acquiring HIV sexually.
86593	Syphilis test, non-treponemal antibody; quantitative	
86780	Treponema pallidum	
84702	Gonadotropin, chorionic (hCG); quantitative	Persons with childbearing potential must be tested for pregnancy at baseline and should be tested again periodically thereafter consistent with CDC guidelines until PrEP is stopped so that pregnant patients, together with their health care providers, can make a fully informed and individualized decision about taking PrEP.
84703	Gonadotropin, chorionic (hCG); qualitative	
84705	Urine pregnancy test, by visual color comparison methods	
99401-99404	Preventive medicine counseling and/or risk factor reduction intervention(s) provided to an individual (separate procedure)* * Any E&M service reported on the same day must be distinct and reported with modifier 25, and time spent providing these services may not be used as a basis for the E&M selection	Adherence counseling – Persons taking PrEP must be offered regular counseling for assessment of behavior and adherence consistent with CDC guidelines to ensure that PrEP is used as prescribed and to maximize PrEP's effectiveness. Sexually transmitted infection (STI) screening and counseling - Persons taking PrEP must be screened for STIs at baseline and should be screened periodically thereafter consistent with CDC guidelines, together with behavioral counseling, which are recommended to reduce the risk of STIs.

HIV Screening for Community Care and MassHealth members

HIV screening for Community Care and MassHealth members is covered in accordance with the USPSTF A and B Recommendations in effect at the time the service is rendered (Human Immunodeficiency Virus (HIV) Infection: Screening (Updated June 11, 2019).

A Recommendation: The USPSTF recommends that clinicians screen for HIV infection in adolescents and adults aged 15 to 65 years. Younger adolescents and older adults who are at increased risk of infection should also be screened. See the Clinical Considerations section for more information about assessment of risk,

A Recommendation: The USPSTF recommends that clinicians screen for HIV infection in all pregnant persons, including those who present in labor or at delivery whose HIV status is unknown.

Current CDC guidelines recommend testing for HIV infection with an antigen/antibody immunoassay approved by the US Food and Drug Administration that detects HIV-1 and HIV-2 antibodies and the HIV-1 p24 antigen, with supplemental testing following a reactive assay to differentiate between HIV-1 and HIV-2 antibodies. If supplemental testing for HIV-1/HIV-2 antibodies is nonreactive or indeterminate (or if acute HIV infection or recent exposure is suspected or reported), an HIV-1 nucleic acid test is recommended to differentiate acute HIV-1 infection from a false-positive test result. (CDC 2018 Quick reference guide: Recommended laboratory HIV testing algorithm for serum or plasma specimens, Updated January 2018).

The USPSTF found insufficient evidence to determine appropriate or optimal time intervals or strategies for repeat HIV screening. However, repeat screening is reasonable for persons known to be at increased risk of HIV infection, such as sexually active men who have sex with men; persons with a sex partner who is living with HIV; or persons who engage in behaviors that may convey an increased risk of HIV infection, such as injection drug use, transactional sex or commercial sex work, having 1 or more new sex partners whose HIV status is unknown, or having other factors that can place a person at increased risk of HIV infection (see “Risk Assessment”). Repeat screening is also reasonable for persons who live or receive medical care in a high-prevalence setting, such as a sexually transmitted disease clinic, tuberculosis clinic, correctional facility, or homeless shelter.

The CDC and ACOG recommend repeat prenatal screening for HIV during the third trimester of pregnancy in women with risk factors for HIV acquisition and in women living or receiving care in high-incidence settings, and the CDC notes that repeat screening for HIV during the third trimester may be considered in all women.

Code	Description	Guidance/Instructions
86701	HIV-1	For Community Care and MassHealth members, HIV screening is covered in accordance with the USPSTF A and B Recommendations in effect at the time the service is rendered: Human Immunodeficiency Virus (HIV) Infection: Screening (Updated June 11, 2019).
86702	HIV-2	
86703	Antibody; HIV-1 and HIV-2, single result	
87389	HIV-1 antigen(s), with HIV-1 and HIV-2 antibodies, single result	
87535	HIV-1, amplified probe technique, includes reverse transcription when performed	
80081	Obstetric panel (includes HIV testing) This panel must include the following: Blood count, complete (CBC), and automated differential WBC count (85025 or 85027 and 85004) OR Blood count, complete (CBC), automated (85027) and appropriate manual differential WBC count (85007 or 85009) Hepatitis B surface antigen (HBsAg) (87340) HIV-1 antigen(s), with HIV-1 and HIV-2 antibodies, single result (87389) Antibody, rubella (86762) Syphilis test, non-treponemal antibody; qualitative (eg, VDRL, RPR, ART) (86592) Antibody screen, RBC, each serum technique (86850) Blood typing, ABO (86900) AND Blood typing, Rh (D) (86901)	ICD-10 Codes: Z11.4 - Encounter for screening for HIV O09.00-O09.93 Supervision of high risk pregnancy Z34.00-Z39.2 Encounter for supervision of normal pregnancy

HIV screening for Medicare members

Screening for HIV is covered for Medicare plan members in accordance with Medicare NCD HIV Screening (210.7):

- Annually for patients ages 15–65, without regard to perceived risk
- Annually for patients younger than 15 and adults older than 65 at increased HIV risk
- For pregnant patients, 3 times per pregnancy:
 - When diagnosed as pregnant,
 - During third trimester, and
 - At labor, if their clinician orders it

Code	Description	Guidance/Instructions
G0432	Infectious agent antibody detection by enzyme immunoassay (eia) technique, hiv-1 and/or hiv-2, screening	For Medicare members, HIV screening is covered in accordance with Medicare NCD HIV Screening (210.7), Version 2, Effective 04/13/2015 ICD-10 Codes:
G0433	Infectious agent antibody detection by enzyme-linked immunosorbent assay (elisa) technique, hiv-1 and/or hiv-2, screening	
G0435	Infectious agent antibody detection by rapid antibody test, hiv-1 and/or hiv-2, screening	
G0475	Hiv antigen/antibody, combination assay, screening	
80081	Obstetric panel (includes HIV testing) This panel must include the following: Blood count, complete (CBC), and automated differential WBC count (85025 or 85027 and 85004) OR Blood count, complete (CBC), automated (85027) and appropriate manual differential WBC count (85007 or 85009) Hepatitis B surface antigen (HBsAg) (87340) HIV-1 antigen(s), with HIV-1 and HIV-2 antibodies, single result (87389) Antibody, rubella (86762) Syphilis test, non-treponemal antibody; qualitative (eg, VDRL, RPR, ART) (86592) Antibody screen, RBC, each serum technique (86850) Blood typing, ABO (86900) AND Blood typing, Rh (D) (86901)	<ul style="list-style-type: none"> • Increased risk factors not reported: Z11.4 • Increased risk factors reported: Z11.4 and Z72.51, Z72.52, Z72.53, or Z72.89 • Pregnant patients: Z11.4 and Z34.00, Z34.01, Z34.02, Z34.03, Z34.80, Z34.81, Z34.82, Z34.83, Z34.90, Z34.91, Z34.92, Z34.93, O09.90, O09.91, O09.92, or O09.93

Lactation

Code	Description	Guidance/Instructions
S9443	Lactation classes, nonphysician provider, per session	Lactation counseling services performed within the scope of an office visit will not separately be reimbursed. Services may require member reimbursement.
E0603	Breast pump, electric (AC and/or DC), any type	Prior authorization may be required based on plan type.

Lung Cancer Screening

What's new: CMS reconsidered the NCD for lung cancer screening with low dose computed tomography (LDCT) (210.14) and determined that the evidence is sufficient to expand eligibility, effective February 10, 2022, to include Medicare beneficiaries who meet all of the following criteria:

- Age 50 – 77 years;
- Asymptomatic (no signs or symptoms of lung cancer);
- Tobacco smoking history of at least 20 pack-years (one pack-year = smoking one pack per day for one year; 1 pack = 20 cigarettes);
- Current smoker or one who has quit smoking within the last 15 years; and

- Receive an order for lung cancer screening with LDCT.

Per NCD 210.14, before a Medicare beneficiary’s first LDCT screening, the beneficiary must receive a counseling and shared decision-making visit that is appropriately documented in the beneficiary’s medical records (see **Counseling and Shared Decision-Making Visit Prior to First Lung Cancer Screening for Medicare plan members** below).

What’s new: Effective March 9, 2021, the USPSTF recommends annual screening for lung cancer with low-dose computed tomography (LDCT) in adults aged 50 to 80 years who have a 20 pack-year smoking history and currently smoke or have quit within the past 15 years. Previously the USPSTF recommended screening in adults aged 55 to 80 years with a 30 pack-year smoking history. Screening should be discontinued once a person has not smoked for 15 years or develops a health problem that substantially limits life expectancy or the ability or willingness to have curative lung surgery.

Code	Description	Guidance/Instructions
71271	<p>Computed tomography (CT), thorax, low dose for lung cancer screening, without contrast material(s)</p> <p>Note: Effective January 1, 2021 HCPCS code G0297 has been replaced by new CPT code 71271.</p>	<p>Prior authorization is required for LDCT for lung cancer screening (CPT 71271) for commercial and MassHealth ACO plan members.</p> <p>Effective September 1, 2021, prior authorization is not required for CPT 71271 for Medicare Advantage, NaviCare and PACE plan members.</p> <p>For commercial and MassHealth members, annual lung cancer screening using LDCT is covered in accordance with the USPSTF Recommendation for Lung Cancer Screening (updated March 9, 2021).</p> <p>For Medicare members, annual lung cancer screening using LDCT is covered in accordance with the Medicare NCD for Lung Cancer Screening with Low Dose Computed Tomography (210.14).⁶</p> <p>ICD-10-CM Diagnosis Codes: F17.210, F17.211, F17.213, F17.218, F17.219, Z87.891</p>

⁶ LDCT lung cancer screening for Medicare members must be furnished in a radiology imaging facility that utilizes a standardized lung nodule identification, classification and reporting system per Medicare NCD 210.14. Additionally, the reading radiologist must have board certification or board eligibility with the American Board of Radiology or equivalent organization..

Counseling and Shared Decision-Making Visit Prior to First Lung Cancer Screening for Medicare plan members

Code	Description	Guidance/Instructions
G0296	Counseling visit to discuss need for lung cancer screening using low dose CT scan (LDCT) (service is for eligibility determination and shared decision making)	Covered for Medicare plan members only. This counseling visit is required prior to the first lung cancer screening using LDCT per Medicare NCD for Lung Cancer Screening with Low Dose Computed Tomography (210.14). The counseling and shared decision-making visit must be appropriately documented in the plan member's medical records. ICD-10-CM Diagnosis Codes: F17.210, F17.211, F17.213, F17.218, F17.219, Z87.891

Osteoporosis Screening

Code	Description	Guidance/Instructions
77080	Dual-energy X-ray absorptiometry (DXA), bone density study, 1 or more sites; axial skeleton (eg, hips, pelvis, spine)	Only considered preventative if billed within the USPSTF <u>Recommendation</u> for woman 65 years and older or those with an increased risk below 65 as outlined in a formal clinical risk assessment tool

Other Preventive wellness screenings

Code	Description	Guidance/Instructions
80048	Basic metabolic panel (Calcium, total)	No specific billing instructions
80061	Lipid panel	
82043	Albumin; urine (eg, microalbumin), quantitative	
83036	Hemoglobin; glycosylated (A1C)	

Preventive Exams

Code	Description	Guidance/Instructions
99381	Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; infant (age younger than 1 year)	No specific billing instructions. Coverage is subject to the code being on the provider's contract.
99382	Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of	

	laboratory/diagnostic procedures, new patient; early childhood (age 1 through 4 years)	
99383	Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; late childhood (age 5 through 11 years)	
99384	Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; adolescent (age 12 through 17 years)	
99385	Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; 18-39 years	
99386	Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; 40-64 years	
99387	Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; 65 years and older	
99391	Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; infant (age younger than 1 year)	
99392	Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; early childhood (age 1 through 4 years)	
99393	Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk	

	factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; late childhood (age 5 through 11 years)	
99394	Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; adolescent (age 12 through 17 years)	
99395	Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; 18-39 years	
99396	Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; 40-64 years	
99397	Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; 65 years and older	
99401	Preventive medicine counseling and/or risk factor reduction intervention(s) provided to an individual (separate procedure); approximately 15 minutes	
99402	Preventive medicine counseling and/or risk factor reduction intervention(s) provided to an individual (separate procedure); approximately 30 minutes	
99403	Preventive medicine counseling and/or risk factor reduction intervention(s) provided to an individual (separate procedure); approximately 45 minutes	
99404	Preventive medicine counseling and/or risk factor reduction intervention(s) provided to an individual (separate procedure); approximately 60 minutes	
S0610	Annual gynecological examination, new patient	
S0612	Annual gynecological examination, established patient	
S0613	Annual gynecological examination; clinical breast examination without pelvic evaluation	

Syphilis Screening

Code	Description	Guidance/Instructions
86592	Syphilis test, non-treponemal antibody; qualitative (eg, VDRL, RPR, ART)	The USPSTF has recommends screening for <u>Pregnant Women</u> and those with <u>Those with Increased</u>
86593	Syphilis test, non-treponemal antibody; quantitative	

		<p><u>Risk</u></p> <p>Use an appropriate pregnancy screening code or for those with increased risk Z11.3: Encounter for screening for infections with a predominantly sexual mode of transmission</p>
--	--	---

Tobacco Cessation Counseling

Code	Description	Guidance/Instructions
99406	Smoking and tobacco use cessation counseling visit; intermediate, greater than 3 minutes up to 10 minutes	Use diagnosis code Z78.871(Personal history of nicotine dependence)
99407	Smoking and tobacco use cessation counseling visit; intensive, greater than 10 minutes Not covered for MassHealth ACO plan members)	Pharmacy benefits are also available for smoking cessation please consult the Plan's website here
S9453	Smoking cessation classes, nonphysician provider, per session	Services for non-pregnant adults and pregnant woman should be performed based upon the USPTF Recommendation

Vaccines: Please see the Plan's Vaccination Payment Policy.

Vision Screening

Code	Description	Guidance/Instructions
99172	Visual function screening, automated or semi-automated bilateral quantitative determination of visual acuity, ocular alignment, color vision by pseudoisochromatic plates, and field of vision (may include all or some screening of the determination[s] for contrast sensitivity, vision under glare)	The UPSTF indicates screening should be done for children 3-5 years. Recommendation Utilize an encounter code for in the Z00.1 (Encounter for newborn, infant and child health examinations) range.
99173	Screening test of visual acuity, quantitative, bilateral	

Place of service

This policy applies to services rendered in all settings.

Policy history

Origination date: 01/01/2012

Previous revision date(s): 11/01/2014 - Updated discussion of preventive services with evaluation and management codes and moved to Fallon Health template.
11/01/2015 - Annual review and moved to new plan template.
07/01/2016 - Added codes 99497 and 99498.

Connection date & details: May 2017 – Annual review.
July 2018 – Annual review, no updates.
January 2019 – Added coding to billing/coding section.
January 2020 – Annual review, no updates.

July 2021 – Updated Billing/coding guidelines for colorectal cancer screening, hearing screening in children, Hepatitis C virus screening and lung cancer screening.

October 2021 - Updated to reflect that prior authorization is not required for LDCT for lung cancer screening (CPT 71271) for Medicare members.

January 2022 - Updated to include coverage and billing and coding instructions for HIV Preexposure Prophylaxis (PrEP); and billing and coding instructions for screening for behavioral health conditions for MassHealth ACO members from birth to 21 years.

April 2022 – Updated to include new lung cancer screening with low dose computed tomography eligibility criteria for Medicare plan members.

January 2023 – Updated Unhealthy Alcohol Use in Adults, added Screening and Behavioral Counseling Interventions in Primary Care to Reduce Alcohol Misuse for Medicare members, added Screening for asymptomatic bacteriuria in adults, updated Developmental and Behavioral Health Screening in Pediatric Primary Care, updated Colorectal Cancer Screening.

April 2023 – Added CPT 84703, 84705 and 87535 to Recommended CPT codes for PrEP billing; updated HIV Screening section.

The criteria listed above apply to Fallon Health plan and its subsidiaries. This payment policy has been developed to provide information regarding general billing, coding, and documentation guidelines for the Plan. Even though this payment policy may indicate that a particular service or supply is considered covered, specific provider contract terms and/or member individual benefit plans may apply and this policy is not a guarantee of payment. The Plan reserves the right to apply this payment policy to all of the Plan companies and subsidiaries. The Plan routinely verifies that charges billed are in accordance with the guidelines stated in this payment policy and are appropriately documented in the medical records. Payments are subject to post-payment audits and retraction of overpayments.